Rejuvenate Bio Appoints Deborah Ascheim, M.D., as Chief Medical Officer

Rejuvenate Bio, today announced the appointment of Deborah Ascheim, M.D., as Chief Medical Officer. In this inaugural role, she will oversee clinical development and regulatory activities and lead the strategy, design and execution of clinical trials to advance a pipeline of gene therapy programs for chronic age-related diseases.